327 related articles for article (PubMed ID: 37867526)
21. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma.
van Berkel A; Rao JU; Kusters B; Demir T; Visser E; Mensenkamp AR; van der Laak JA; Oosterwijk E; Lenders JW; Sweep FC; Wevers RA; Hermus AR; Langenhuijsen JF; Kunst DP; Pacak K; Gotthardt M; Timmers HJ
J Nucl Med; 2014 Aug; 55(8):1253-9. PubMed ID: 24925884
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Pheochromocytoma Cells with Recurrent Cycles of Hypoxia: A New Pseudohypoxic In Vitro Model.
Helm J; Drukewitz S; Poser I; Richter S; Friedemann M; William D; Mohr H; Nölting S; Robledo M; Bornstein SR; Eisenhofer G; Bechmann N
Cells; 2022 Feb; 11(3):. PubMed ID: 35159368
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia-inducible Factor 2α: A Key Player in Tumorigenesis and Metastasis of Pheochromocytoma and Paraganglioma?
Bechmann N; Eisenhofer G
Exp Clin Endocrinol Diabetes; 2022 May; 130(5):282-289. PubMed ID: 34320663
[TBL] [Abstract][Full Text] [Related]
24. PHEOCHROMOCYTOMA: A GENETIC AND DIAGNOSTIC UPDATE.
Mercado-Asis LB; Wolf KI; Jochmanova I; Taïeb D
Endocr Pract; 2018 Jan; 24(1):78-90. PubMed ID: 29144820
[TBL] [Abstract][Full Text] [Related]
25. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Gaal J; Burnichon N; Korpershoek E; Roncelin I; Bertherat J; Plouin PF; de Krijger RR; Gimenez-Roqueplo AP; Dinjens WN
J Clin Endocrinol Metab; 2010 Mar; 95(3):1274-8. PubMed ID: 19915015
[TBL] [Abstract][Full Text] [Related]
26. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
Baysal BE; Maher ER
Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
[TBL] [Abstract][Full Text] [Related]
27. Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.
Vicha A; Taieb D; Pacak K
Endocr Relat Cancer; 2014 Jun; 21(3):R261-77. PubMed ID: 24500761
[TBL] [Abstract][Full Text] [Related]
28. Model systems in SDHx-related pheochromocytoma/paraganglioma.
Takács-Vellai K; Farkas Z; Ősz F; Stewart GW
Cancer Metastasis Rev; 2021 Dec; 40(4):1177-1201. PubMed ID: 34957538
[TBL] [Abstract][Full Text] [Related]
29. Succinate Mediates Tumorigenic Effects
Matlac DM; Hadrava Vanova K; Bechmann N; Richter S; Folberth J; Ghayee HK; Ge GB; Abunimer L; Wesley R; Aherrahrou R; Dona M; Martínez-Montes ÁM; Calsina B; Merino MJ; Schwaninger M; Deen PMT; Zhuang Z; Neuzil J; Pacak K; Lehnert H; Fliedner SMJ
Front Endocrinol (Lausanne); 2021; 12():589451. PubMed ID: 33776908
[TBL] [Abstract][Full Text] [Related]
30. Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations.
Zhang J; Jiang J; Luo Y; Li X; Lu Z; Liu Y; Huang J; Hou Y; Pang Y; Sun MYF; Wang TS; Evans DB; Pacak K; Zhuang Z; Gao X
Endocrine; 2018 Aug; 61(2):216-223. PubMed ID: 29846902
[TBL] [Abstract][Full Text] [Related]
31. Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit.
Bancel LP; Masso V; Dessein AF; Aubert S; Leteurtre E; Coppin L; Odou MF; Cao CD; Cardot-Bauters C; Pigny P
J Clin Endocrinol Metab; 2023 Aug; 108(9):2343-2352. PubMed ID: 36848172
[TBL] [Abstract][Full Text] [Related]
32. Pheochromocytoma: Gasping for Air.
Jochmanová I; Zhuang Z; Pacak K
Horm Cancer; 2015 Dec; 6(5-6):191-205. PubMed ID: 26138106
[TBL] [Abstract][Full Text] [Related]
33. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
34. Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings.
Lendvai N; Pawlosky R; Bullova P; Eisenhofer G; Patocs A; Veech RL; Pacak K
Endocrinology; 2014 Jan; 155(1):27-32. PubMed ID: 24189137
[TBL] [Abstract][Full Text] [Related]
35. Targeted Therapies in Pheochromocytoma and Paraganglioma.
Wang K; Crona J; Beuschlein F; Grossman AB; Pacak K; Nölting S
J Clin Endocrinol Metab; 2022 Nov; 107(11):2963-2972. PubMed ID: 35973976
[TBL] [Abstract][Full Text] [Related]
36. Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma.
Murakami M; Sun N; Greunke C; Feuchtinger A; Kircher S; Deutschbein T; Papathomas T; Bechmann N; William Wallace P; Peitzsch M; Korpershoek E; Friemel J; Gimenez-Roqueplo AP; Robledo M; J L M Timmers H; Canu L; Weber A; R de Krijger R; Fassnacht M; Knösel T; Kirchner T; Reincke M; Karl Walch A; Kroiss M; Beuschlein F
Eur J Endocrinol; 2021 Jun; 185(1):179-191. PubMed ID: 33983135
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors.
Xiao M; Yang H; Xu W; Ma S; Lin H; Zhu H; Liu L; Liu Y; Yang C; Xu Y; Zhao S; Ye D; Xiong Y; Guan KL
Genes Dev; 2012 Jun; 26(12):1326-38. PubMed ID: 22677546
[TBL] [Abstract][Full Text] [Related]
38. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
39. New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications.
Jhawar S; Arakawa Y; Kumar S; Varghese D; Kim YS; Roper N; Elloumi F; Pommier Y; Pacak K; Del Rivero J
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158861
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
